title: Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes.
abstract: BACKGROUND
  In animal and observational studies, adiponectin is associated with lipoprotein risk factors for cardiovascular disease.
  
  
  OBJECTIVE
  We analyzed data from a randomized clinical trial to evaluate the relationship between changes in adiponectin to changes in lipoprotein risk factors after an intervention that alters adiponectin levels.
  
  
  METHODS
  Adiponectin levels were measured at baseline and follow-up, as were lipoprotein risk factors for cardiovascular disease, at academic medical centers and ambulatory care centers.
  
  
  METHODS
  Participants included 361 men and women with type 2 diabetes.
  
  
  METHODS
  Intervention included randomization to treatment with glimepiride or pioglitazone for 72 wk.
  
  
  METHODS
  The relationship of treatment-related differences in adiponectin level to treatment-related differences in lipoprotein cardiovascular risk factors at 72 wk was evaluated.
  
  
  RESULTS
  Pioglitazone led to an increase in adiponectin compared with glimepiride. Compared with baseline, pioglitazone treatment at 72 wk led to an increase in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and a decrease in very-low-density lipoprotein (VLDL) particle size and LDL particle number. Glimepiride treatment more modestly decreased LDL particle number and increased LDL particle size. At 72 wk, there were significant treatment group differences for HDL, LDL, and VLDL particle size, and triglyceride and HDL cholesterol level. The increase in adiponectin predicted treatment-related improvement for triglyceride and HDL cholesterol level and LDL and HDL particle size.
  
  
  CONCLUSIONS
  Increased adiponectin contributed to treatment-related benefit in lipoprotein cardiovascular disease risk factors in obese diabetic subjects treated with pioglitazone. These results provide support for a model that mechanistically links changes in adiponectin level to changes in lipoprotein composition in humans.
authors.affiliation: Department of Medicine, University of Illinois at Chicago, 1819 West Polk Street, Chicago, Illinois 60612, USA.
authors.forename: Susan
authors.initials: S
authors.lastname: Sam
authors.forename: Steven
authors.initials: S
authors.lastname: Haffner
authors.forename: Michael H
authors.initials: MH
authors.lastname: Davidson
authors.forename: Ralph
authors.initials: R
authors.lastname: D'Agostino
authors.forename: Alfonso
authors.initials: A
authors.lastname: Perez
authors.forename: Theodore
authors.initials: T
authors.lastname: Mazzone
mesh_terms: D052242:Adiponectin / Q000097:blood / Q000737:chemistry; D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000187:drug effects; D008074:Lipoproteins / Q000737:chemistry / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D000077205:Pioglitazone; D011379:Prognosis; D013453:Sulfonylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D007004:Hypoglycemic Agents; D008074:Lipoproteins; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; C057619:glimepiride; D000077205:Pioglitazone
references.citation: J Clin Endocrinol Metab. 2009 Mar;94(3):989-97
references.pmid: 19116237
references.citation: FEBS Lett. 2007 Oct 30;581(26):5029-33
references.pmid: 17936760
references.citation: Endocr Rev. 2005 May;26(3):439-51
references.pmid: 15897298
references.citation: JAMA. 2009 Jul 8;302(2):179-88
references.pmid: 19584347
references.citation: Diabetes. 2003 Feb;52(2):453-62
references.pmid: 12540621
references.citation: Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1364-9
references.pmid: 16574896
references.citation: Diabetes. 2005 Feb;54(2):534-9
references.pmid: 15677512
references.citation: Diabetologia. 1985 Jul;28(7):412-9
references.pmid: 3899825
references.citation: Circulation. 2008 Apr 22;117(16):2123-30
references.pmid: 18413496
references.citation: Diabetes. 2008 Aug;57(8):2022-7
references.pmid: 18469202
references.citation: Diabetes Care. 2009 Jul;32(7):1317-9
references.pmid: 19389813
references.citation: JAMA. 2006 Dec 6;296(21):2572-81
references.pmid: 17101640
references.citation: J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S64-73
references.pmid: 18987272